Alentis Therapeutics’ CLDN1-targeting antibody cleared to enter clinic in US for head and neck cancer
June 15, 2023
Alentis Therapeutics AG has received FDA clearance of the company’s IND application for ALE.C04, a first-in-class monoclonal antibody developed to specifically target exposed Claudin-1 (CLDN1) on cancer cells.